Rokibul Hasan Bhuiyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rokibul Hasan Bhuiyan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Sadikuj Jaman
Department of Biochemistry and Molecular Biology, University of Rajshahi-6205, Bangladesh
3 shared publications - Dipongkar Ray Sobuj
Department of Chemistry and Biochemistry, Lamar University
2 shared publications - Md. Maniruzzaman
Department of Pharmacy, School of Science & Technology, Varendra University, Rajshahi-6204, Bangladesh
2 shared publications - Md. Rakib Rased Rana
Department of Pharmacy, School of Science & Technology, Varendra University, Rajshahi-6204, Bangladesh
2 shared publications - Tamanna Rashid
Department of Chemistry and Biochemistry, Lamar University
2 shared publications Maniruzzaman
Department of Pharmacy , Varendra University , Rajshahi , Bangladesh
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by E-palli in American Journal of Chemistry and Pharmacy
- Vol. 5 (2) , 31-47
Advances in the Use of Natural Compounds for Cancer Therapy: A Transition from Traditional Approaches to Modern Drug Guidance
Cancer is one of the most serious and leading causes of death worldwide. Many individuals incorporate natural and nutritious foods into their diets which can help prevent cancer and reduce other health risks. Although synthetic drugs are commonly used in cancer treatment and their effectiveness is often limited by drug resistance and adverse side effects. So, physicians and researchers are increasingly focusing on natural products to enhance efficacy of conventional cancer therapies and to minimize associated toxicities. A comprehensive literature search was conducted primarily in google scholar and was supplemented by searches in PubMed, Scopus and Science Direct using relevant keywords. We found that same natural product can inhibit multiple types of cancer and may also be used in combination with pharmaceutical drugs. Important fact is that many people are unaware of anticancer activities of natural products and their potential benefits. It is equally important to highlight limitations of conventional pharmaceutical treatments. So affordable yet valuable natural products should be recognized and further investigated for their therapeutic potential in cancer prevention and treatment. This study aims to discuss different types of cancer and their relationship with natural products as well as anticancer drugs. The main objective is to investigate activity of natural products against various cancer cell types and to compare their effectiveness with that of synthetic drugs used alone. This approach may help bridge traditional and modern treatments and contributing to advancement of cancer therapy in general.
- 17 September 2026
- Published by E-palli in American Journal of Chemistry and Pharmacy
- Vol. 5 (2) , 31-47
Open AccessAdvances in the Use of Natural Compounds for Cancer Therapy: A Transition from Traditional Approaches to Modern Drug Guidance
Cancer is one of the most serious and leading causes of death worldwide. Many individuals incorporate natural and nutritious foods into their diets which can help prevent cancer and reduce other health risks. Although synthetic drugs are commonly used in cancer treatment and their effectiveness is often limited by drug resistance and adverse side effects. So, physicians and researchers are increasingly focusing on natural products to enhance efficacy of conventional cancer therapies and to minimize associated toxicities. A comprehensive literature search was conducted primarily in google scholar and was supplemented by searches in PubMed, Scopus and Science Direct using relevant keywords. We found that same natural product can inhibit multiple types of cancer and may also be used in combination with pharmaceutical drugs. Important fact is that many people are unaware of anticancer activities of natural products and their potential benefits. It is equally important to highlight limitations of conventional pharmaceutical treatments. So affordable yet valuable natural products should be recognized and further investigated for their therapeutic potential in cancer prevention and treatment. This study aims to discuss different types of cancer and their relationship with natural products as well as anticancer drugs. The main objective is to investigate activity of natural products against various cancer cell types and to compare their effectiveness with that of synthetic drugs used alone. This approach may help bridge traditional and modern treatments and contributing to advancement of cancer therapy in general.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2026 (1) , 2576658
The Roles of MicroRNAs, Oncogenes, and Tumor Suppressor Gene Molecular Subtypes of Breast Cancer: Therapeutic Potential of Pharmaceutical and Natural Products
Background: Breast cancer (BC) is the most common malignancy among women, with 2.3 million new cases and over 670,000 deaths annually. Despite advances in detection and therapy, relapse, metastasis, and resistance remain significant challenges. Tumor suppressor genes (TSGs) regulate abnormal cell division, whereas oncogenes, which arise from proto‐oncogenes, can inhibit TSGs and promote cancer progression. MicroRNAs further influence cellular processes in both normal and malignant states. Pharmaceutical agents such as tamoxifen and paclitaxel have demonstrated efficacy, while natural products, including baicalin and ursolic acid, show promise in modulating oncogenic pathways. Understanding BC subtypes is crucial, as they guide prognosis and enable more precise and personalized treatment strategies. These insights emphasize the complex molecular landscape and evolving approaches to BC therapy. Objective: The review was conducted using a defined set of keywords to search PubMed, Web of Science, Embase, Scopus, Google Scholar, and SciSearch databases covering publications from the inception of each database through August 2, 2025. Key Findings: This review outlines BC subtypes and their molecular features, highlighting TSGs, oncogenes, and miRNAs as therapeutic targets. Both synthetic drugs and natural compounds demonstrate potential applications in advancing BC treatment strategies. Conclusion: BC subtypes, defined by morphology and molecular features, remain vital for targeted therapy advancement. TSGs, oncogenes, and miRNAs play key roles in subtype regulation and require further study for precise detection and treatment. Synthetic drugs and natural compounds show promise as therapeutic agents. However, continued molecular research is essential to improve personalized strategies and overcome relapse, metastasis, and resistance in BC management.
- 1 January 2026
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2026 (1) , 2576658
Open AccessThe Roles of MicroRNAs, Oncogenes, and Tumor Suppressor Gene Molecular Subtypes of Breast Cancer: Therapeutic Potential of Pharmaceutical and Natural Products
Background: Breast cancer (BC) is the most common malignancy among women, with 2.3 million new cases and over 670,000 deaths annually. Despite advances in detection and therapy, relapse, metastasis, and resistance remain significant challenges. Tumor suppressor genes (TSGs) regulate abnormal cell division, whereas oncogenes, which arise from proto‐oncogenes, can inhibit TSGs and promote cancer progression. MicroRNAs further influence cellular processes in both normal and malignant states. Pharmaceutical agents such as tamoxifen and paclitaxel have demonstrated efficacy, while natural products, including baicalin and ursolic acid, show promise in modulating oncogenic pathways. Understanding BC subtypes is crucial, as they guide prognosis and enable more precise and personalized treatment strategies. These insights emphasize the complex molecular landscape and evolving approaches to BC therapy. Objective: The review was conducted using a defined set of keywords to search PubMed, Web of Science, Embase, Scopus, Google Scholar, and SciSearch databases covering publications from the inception of each database through August 2, 2025. Key Findings: This review outlines BC subtypes and their molecular features, highlighting TSGs, oncogenes, and miRNAs as therapeutic targets. Both synthetic drugs and natural compounds demonstrate potential applications in advancing BC treatment strategies. Conclusion: BC subtypes, defined by morphology and molecular features, remain vital for targeted therapy advancement. TSGs, oncogenes, and miRNAs play key roles in subtype regulation and require further study for precise detection and treatment. Synthetic drugs and natural compounds show promise as therapeutic agents. However, continued molecular research is essential to improve personalized strategies and overcome relapse, metastasis, and resistance in BC management.
- 31 December 2025
- Published by Research Synergy Foundation in Journal of Healthcare and Biomedical Science
- Vol. 4 (1)
radioprotector and natural products
Background: Cancer remains one of the most significant global health challenges and radiotherapy continues to be one of the most effective treatment options. However, Patients are also exposed to low doses of ionizing radiation during diagnostic procedures such as computed tomography (CT) and magnetic resonance imaging (MRI). These exposures can induce various cellular and molecular defects in the human body. Therefore, there is an urgent need to develop safer and more reliable radioprotective agents to minimize radiation induced damage. Method: This review was prepared using selected keywords searched across major scientific databases including ScienceDirect, PubMed, Web of Science, MEDLINE, Embase, Scopus, Google Scholar and SCISEARCH covering publications from the inception of each data base up to October 14, 2025. Key findings: This review discusses various plants with reported radioprotective properties and compares the significance of naturally derived and pharmaceutical radioprotective agents. Conclusion: Radioprotective agents offer several advantages in both oncotherapy and diagnostic applications. However, many synthetic radioprotectors are associated with limitations such as high cost, short duration of action, toxicity and adverse effects on the central nervous system. In contrast natural radioprotectors derived from plants have shown the potential to safeguard normal cells from radiation induced radioprotectors derived from plants have shown the potential to safeguard normal cells from radiation induced damage more effectively and safely than their synthetic counterparts. The aim of this review is to identify safer and more effective radioprotective agents for use by oncologists and radiation biologists.
- 31 December 2025
- Published by Research Synergy Foundation in Journal of Healthcare and Biomedical Science
- Vol. 4 (1)
radioprotector and natural products
Background: Cancer remains one of the most significant global health challenges and radiotherapy continues to be one of the most effective treatment options. However, Patients are also exposed to low doses of ionizing radiation during diagnostic procedures such as computed tomography (CT) and magnetic resonance imaging (MRI). These exposures can induce various cellular and molecular defects in the human body. Therefore, there is an urgent need to develop safer and more reliable radioprotective agents to minimize radiation induced damage. Method: This review was prepared using selected keywords searched across major scientific databases including ScienceDirect, PubMed, Web of Science, MEDLINE, Embase, Scopus, Google Scholar and SCISEARCH covering publications from the inception of each data base up to October 14, 2025. Key findings: This review discusses various plants with reported radioprotective properties and compares the significance of naturally derived and pharmaceutical radioprotective agents. Conclusion: Radioprotective agents offer several advantages in both oncotherapy and diagnostic applications. However, many synthetic radioprotectors are associated with limitations such as high cost, short duration of action, toxicity and adverse effects on the central nervous system. In contrast natural radioprotectors derived from plants have shown the potential to safeguard normal cells from radiation induced radioprotectors derived from plants have shown the potential to safeguard normal cells from radiation induced damage more effectively and safely than their synthetic counterparts. The aim of this review is to identify safer and more effective radioprotective agents for use by oncologists and radiation biologists.